Julio Ramirez, United States of America
University of Louisville School of Medicine Division of Infectious DiseasesPresenter of 7 Presentations
EARLY AND LATE MORTALITY OF ADULTS HOSPITALIZED WITH PNEUMOCOCCAL PNEUMONIA IN THE UNITED STATES (ID 797)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- William Mattingly, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
Abstract
Background
The number of deaths due to pneumococcal pneumonia (PP) in the United States (U.S.) is not well defined. The objectives of this study were to define mortality of PP in the city of Louisville, Kentucky and to estimate the number of deaths in hospitalized patients with PP in the U.S.
Methods
In hospitalized patients with community-acquired pneumonia (CAP), urinary antigen detection of 24 S. pneumoniae serotypes (UAD-24) was performed. This UAD-24 study was nested in a prospective population-based cohort study of all adult residents in Louisville, hospitalized with CAP from 6/1/14 to 5/31/16. Louisville PP mortality was evaluated early (during hospitalization and at 30-days after hospitalization) and late (6-months and 1-year after hospitalization) and US number of deaths were estimated.
Results
A total of 708 patients with PP were evaluated. PP mortality was 3.7% during hospitalization, 8.2% at 30-days, 17.6% at 6-months, and 25.4% at 1-year. Number of deaths in the U.S. were: 8,323 (95%CI:5,468-12,091) during hospitalization, 18,619 (95%CI:14,231-23,711) at 30-days, 39,807 (95%CI:33,506-46,502) at 6 months, and 57,626 (95%CI:50,130-64,940) at 1-year.
Conclusions
In hospitalized patients, PP is associated with significant early and late mortality. Approximately 1 out of 4 hospitalized adult patients with PP will die within 1-year.
EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV-23) IN THE PREVENTION OF HOSPITALIZATIONS DUE TO VACCINE-TYPE PNEUMOCOCCAL PNEUMONIA (ID 811)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- William Mattingly, United States of America
- Forest Arnold, United States of America
- Tim Wiemken, United States of America
- Ruth Carrico, United States of America
- The Louisville Pneumonia Study Group, United States of America
LOW-INCOME LEVEL IS ASSOCIATED WITH HOSPITALIZATION DUE TO PNEUMOCOCCAL PNEUMONIA (ID 800)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Tim Wiemken, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
ASSOCIATION OF S. PNEUMONIAE SEROTYPES WITH MYOCARDIAL INFARCTION AND OTHER CARDIAC EVENTS IN HOSPITALIZED PATIENTS WITH PNEUMOCOCCAL PNEUMONIA (ID 805)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Paula Peyrani, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
S. PNEUMONIAE SEROTYPES IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMOCOCCAL PNEUMONIA AND CLINICAL FAILURE (ID 807)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Forest Arnold, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
ANNUAL NUMBER OF ADULTS HOSPITALIZED WITH PNEUMOCOCCAL PNEUMONIA IN THE UNITED STATES (ID 473)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Forest Arnold, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
IMPACT OF MICROBIOLOGICAL WORKUP ON THE INCIDENCE OF HOSPITALIZATIONS DUE TO PNEUMOCOCCAL PNEUMONIA (ID 809)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- William Mattingly, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
Author Of 8 Presentations
S. PNEUMONIAE SEROTYPES IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMOCOCCAL PNEUMONIA AND CLINICAL FAILURE (ID 807)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Forest Arnold, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
ANNUAL NUMBER OF ADULTS HOSPITALIZED WITH PNEUMOCOCCAL PNEUMONIA IN THE UNITED STATES (ID 473)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Forest Arnold, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
IMPACT OF MICROBIOLOGICAL WORKUP ON THE INCIDENCE OF HOSPITALIZATIONS DUE TO PNEUMOCOCCAL PNEUMONIA (ID 809)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- William Mattingly, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
EARLY AND LATE MORTALITY OF ADULTS HOSPITALIZED WITH PNEUMOCOCCAL PNEUMONIA IN THE UNITED STATES (ID 797)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- William Mattingly, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
Abstract
Background
The number of deaths due to pneumococcal pneumonia (PP) in the United States (U.S.) is not well defined. The objectives of this study were to define mortality of PP in the city of Louisville, Kentucky and to estimate the number of deaths in hospitalized patients with PP in the U.S.
Methods
In hospitalized patients with community-acquired pneumonia (CAP), urinary antigen detection of 24 S. pneumoniae serotypes (UAD-24) was performed. This UAD-24 study was nested in a prospective population-based cohort study of all adult residents in Louisville, hospitalized with CAP from 6/1/14 to 5/31/16. Louisville PP mortality was evaluated early (during hospitalization and at 30-days after hospitalization) and late (6-months and 1-year after hospitalization) and US number of deaths were estimated.
Results
A total of 708 patients with PP were evaluated. PP mortality was 3.7% during hospitalization, 8.2% at 30-days, 17.6% at 6-months, and 25.4% at 1-year. Number of deaths in the U.S. were: 8,323 (95%CI:5,468-12,091) during hospitalization, 18,619 (95%CI:14,231-23,711) at 30-days, 39,807 (95%CI:33,506-46,502) at 6 months, and 57,626 (95%CI:50,130-64,940) at 1-year.
Conclusions
In hospitalized patients, PP is associated with significant early and late mortality. Approximately 1 out of 4 hospitalized adult patients with PP will die within 1-year.
EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV-23) IN THE PREVENTION OF HOSPITALIZATIONS DUE TO VACCINE-TYPE PNEUMOCOCCAL PNEUMONIA (ID 811)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- William Mattingly, United States of America
- Forest Arnold, United States of America
- Tim Wiemken, United States of America
- Ruth Carrico, United States of America
- The Louisville Pneumonia Study Group, United States of America
LOW-INCOME LEVEL IS ASSOCIATED WITH HOSPITALIZATION DUE TO PNEUMOCOCCAL PNEUMONIA (ID 800)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Tim Wiemken, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America
STREPTOCOCCUS PNEUMONIAE SEROTYPE DISTRIBUTION AND COVERAGE OF PNEUMOCOCCAL CONJUGATE VACCINES IN ADULTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA IN THE UNITED STATES (ID 879)
- Lindsay R. Grant, United States of America
- Julio Ramirez, United States of America
- Wesley H. Self, United States of America
- Francis Counselman, United States of America
- Gregory Volturo, United States of America
- Luis Ostrosky-Zeichner, United States of America
- Paula Peyrani, United States of America
- Richard Wunderink, United States of America
- Robert Sherwin, United States of America
- J. Scott Overcash, United States of America
- Thomas File, United States of America
- Michael W. Pride, United States of America
- Sharon L. Gray, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Qin Jiang, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
Abstract
Background
The study objective was to determine the prevalence of serotypes and coverage provided by currently licensed and next generation pneumococcal conjugate vaccines (PCVs) in adults hospitalized with community-acquired pneumonia (CAP) in the United States.
Methods
Hospitalized adults aged ≥18 years with radiologically-confirmed (CXR+) CAP were enrolled from 10 U.S. cities between October 2013 and September 2016. S. pneumoniae isolates cultured from normally-sterile standard-of-care specimens were serotyped by Quellung. Urine was tested using BinaxNOW® and a serotype-specific urine antigen detection (UAD) assay that detects serotypes contained in PCV13 plus 6C (highly-related to 6A), PCV15 (PCV13 serotypes, 22F, and 33F), PCV20 (PCV15 serotypes, 8, 10A, 11A, 12F, and 15B plus 15C (highly-related to 15B)), and non-PCV serotypes 2, 9N, 17F, and 20. Coverage was calculated as the percent of CXR+CAP participants positive for a serotype in PCV13, PCV15, and PCV20.
Results
Of 15,572 enrolled participants, 12,055 with CXR+CAP were included in the analysis; 52.7% (n=6347) were ≥65 years. Coverage of CXR+CAP varied by PCV formulation (Table). About 1% of CXR+CAP was due to serotypes 2, 9N, 17F, and 20 combined.
Conclusions
Compared to PCV13, PCV20 increased coverage of CXR+CAP due to PCV serotypes by 71% (18-64 years) and 64% (≥65 years).
ASSOCIATION OF S. PNEUMONIAE SEROTYPES WITH MYOCARDIAL INFARCTION AND OTHER CARDIAC EVENTS IN HOSPITALIZED PATIENTS WITH PNEUMOCOCCAL PNEUMONIA (ID 805)
- Julio Ramirez, United States of America
- Stephen Furmanek, United States of America
- Senen Pena, United States of America
- Ruth Carrico, United States of America
- Paula Peyrani, United States of America
- Ronika Alexander, United States of America
- Kimbal D. Ford, United States of America
- Sharon L. Gray, United States of America
- Luis Jodar, United States of America
- Raul Isturiz, United States of America
- The Louisville Pneumonia Study Group, United States of America